Related Experiment Video
Updated: Jul 29, 2026
High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
CSF Mitochondrial N-Formyl Methionine Peptide as Complementary Diagnostic Tool in Anti-NMDAR Encephalitis and
Chuo Li1, Jun-Yu Chen2, Yu Peng3
1Department of Neurology, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510440, People's Republic of China.
Background:
Mitochondrial damage is significant in autoimmune diseases, with mitochondrial N-formyl methionine peptide (fMet) being released from damaged mitochondria. However, its potential as a marker for assessing the severity of two kinds of encephalitis - anti-N-methyl-D-aspartate receptor (anti-NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) - remains uncertain. We measured CSF fMet levels in anti-NMDAR encephalitis and anti-LG1 encephalitis patients, assessing its diagnostic and therapeutic potential.
Methods:
Twenty-five patients diagnosed with anti-NMDAR encephalitis and nineteen patients with anti-LGI1 encephalitis were included in the study. Their cerebrospinal fluid (CSF) fMet levels were assessed using enzyme-linked immunosorbent assays.
Results:
The findings revealed a significant increase in CSF fMet levels, which correlated with modified Rankin Scale (mRS) scores in both anti-NMDAR encephalitis and anti-LGI1 encephalitis patients.
Conclusion:
The CSF fMet levels were found to be associated with disease severity in patients diagnosed with both anti-NMDAR encephalitis and anti-LGI1 encephalitis. These findings suggest that preventing mitochondrial damage could serve as an effective treatment strategy for managing these diseases.
Insights
Elevated mitochondrial N-formyl methionine peptide (fMet) in cerebrospinal fluid (CSF) indicates disease severity in autoimmune encephalitis, including anti-N-methyl-D-aspartate receptor (anti-NMDAR) and anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis.
Area of Science:
- Neuroimmunology
- Mitochondrial Biology
- Autoimmune Encephalitis
Background:
- Mitochondrial damage is implicated in autoimmune diseases.
- Mitochondrial N-formyl methionine peptide (fMet) is released from damaged mitochondria.
- The role of fMet as a severity marker in anti-NMDAR and anti-LGI1 encephalitis is unclear.
Purpose of the Study:
- To measure CSF fMet levels in patients with anti-NMDAR and anti-LGI1 encephalitis.
- To assess the diagnostic and therapeutic potential of CSF fMet.
- To correlate CSF fMet levels with disease severity.
Main Methods:
- Enzyme-linked immunosorbent assays (ELISAs) were used to measure CSF fMet levels.
- The study included 25 patients with anti-NMDAR encephalitis and 19 with anti-LGI1 encephalitis.
- Cerebrospinal fluid (CSF) samples were analyzed.
Main Results:
- CSF fMet levels were significantly increased in both encephalitis patient groups.
- Elevated CSF fMet levels correlated with modified Rankin Scale (mRS) scores.
- A strong association was observed between CSF fMet levels and disease severity.
Conclusions:
- CSF fMet levels are associated with disease severity in anti-NMDAR and anti-LGI1 encephalitis.
- Preventing mitochondrial damage may be a therapeutic strategy for these conditions.
- fMet shows potential as a biomarker for autoimmune encephalitis severity.
More Related Videos
07:20A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
Related Concept Videos
01:26Rocky Mountain Spotted Fever
01:19Encephalitis l: Introduction